These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 22313329)

  • 1. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis.
    Dunlop W; Uhl R; Khan I; Taylor A; Barton G
    J Med Econ; 2012; 15(3):564-75. PubMed ID: 22313329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation.
    Poelaert J; Koopmans-Klein G; Dioh A; Louis F; Gorissen M; Logé D; Van Op den Bosch J; van Megen YJ
    Clin Ther; 2015 Apr; 37(4):784-92. PubMed ID: 25757607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of oxycodone with naloxone versus oxycodone alone for the management of moderate-to-severe pain in patients with opioid-induced constipation in Canada.
    Goeree R; Goeree J
    J Med Econ; 2016; 19(3):277-91. PubMed ID: 26535790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial.
    Leng X; Zhang F; Yao S; Weng X; Lu K; Chen G; Huang M; Huang Y; Zeng X; Hopp M; Lu G
    Adv Ther; 2020 Mar; 37(3):1188-1202. PubMed ID: 32020565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed ratio (2:1) prolonged-release oxycodone/naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxatives.
    Koopmans G; Simpson K; De Andrés J; Lux EA; Wagemans M; Van Megen Y
    Curr Med Res Opin; 2014 Nov; 30(11):2389-96. PubMed ID: 25265132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial.
    Löwenstein O; Leyendecker P; Hopp M; Schutter U; Rogers PD; Uhl R; Bond S; Kremers W; Nichols T; Krain B; Reimer K
    Expert Opin Pharmacother; 2009 Mar; 10(4):531-43. PubMed ID: 19243306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis.
    Lazzari M; Greco MT; Marcassa C; Finocchi S; Caldarulo C; Corli O
    Drug Des Devel Ther; 2015; 9():5863-72. PubMed ID: 26586937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged release oxycodone and naloxone treatment counteracts opioid-induced constipation in patients with severe pain compared to previous analgesic treatment.
    Koopmans-Klein G; Van Op den Bosch J; van Megen Y; Prenen H; Huygen F; Mancini I
    Curr Med Res Opin; 2017 Dec; 33(12):2217-2227. PubMed ID: 28805471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study.
    Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
    Eur J Pain; 2017 Oct; 21(9):1485-1494. PubMed ID: 28474460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations.
    Ueberall MA; Mueller-Schwefe GH
    Curr Med Res Opin; 2015; 31(7):1413-29. PubMed ID: 25942606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical and economical evaluation of new analgesics for the management of chronic pain].
    Coluzzi F; Ruggeri M
    Recenti Prog Med; 2014 Nov; 105(11):415-9. PubMed ID: 25424235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials.
    Blagden M; Hafer J; Duerr H; Hopp M; Bosse B
    Neurogastroenterol Motil; 2014 Dec; 26(12):1792-801. PubMed ID: 25346155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation.
    Lazzari M; Marcassa C; Natoli S; Carpenedo R; Caldarulo C; Silvi MB; Dauri M
    Clin Interv Aging; 2016; 11():641-9. PubMed ID: 27257377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ENhANCE trial protocol: A multi-centre, randomised, phase IV trial comparing the efficacy of oxycodone/naloxone prolonged release (OXN PR) versus oxycodone prolonged release (Oxy PR) tablets in patients with advanced cancer.
    Wong AK; Grobler A; Le B
    Contemp Clin Trials Commun; 2022 Dec; 30():101036. PubMed ID: 36407843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid-Induced Constipation Relief From Fixed-Ratio Combination Prolonged-Release Oxycodone/Naloxone Compared With Oxycodone and Morphine for Chronic Nonmalignant Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Huang L; Zhou JG; Zhang Y; Wang F; Wang Y; Liu DH; Li XJ; Lv SP; Jin SH; Bai YJ; Ma H
    J Pain Symptom Manage; 2017 Nov; 54(5):737-748.e3. PubMed ID: 28736104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain.
    Ahmedzai SH; Nauck F; Bar-Sela G; Bosse B; Leyendecker P; Hopp M
    Palliat Med; 2012 Jan; 26(1):50-60. PubMed ID: 21937568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial.
    Trenkwalder C; Chaudhuri KR; Martinez-Martin P; Rascol O; Ehret R; Vališ M; Sátori M; Krygowska-Wajs A; Marti MJ; Reimer K; Oksche A; Lomax M; DeCesare J; Hopp M;
    Lancet Neurol; 2015 Dec; 14(12):1161-70. PubMed ID: 26494524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR.
    Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
    Eur J Pain; 2017 Oct; 21(9):1528-1537. PubMed ID: 28641363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine.
    Ikenberg R; Hertel N; Moore RA; Obradovic M; Baxter G; Conway P; Liedgens H
    J Med Econ; 2012; 15(4):724-36. PubMed ID: 22364286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone.
    Morlion B; Clemens KE; Dunlop W
    Clin Drug Investig; 2015 Jan; 35(1):1-11. PubMed ID: 25479959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.